Free Access
Med Sci (Paris)
Volume 22, Number 3, Mars 2006
Page(s) 259 - 265
Section M/S revues
Published online 15 March 2006
  1. McCay CM, Crowell MF. Prolonging the lifespan. Scientific Monthly 1934; 39 : 405–14. [Google Scholar]
  2. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature 1996; 384 : 33. [Google Scholar]
  3. Bartke A, Wright JC, Mattison JA, et al. Extending the lifespan of long-lived mice. Nature 2001; 414 : 412. [Google Scholar]
  4. Kenyon C. A conserved regulatory system for aging. Cell 2001; 105 : 165–8. [Google Scholar]
  5. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75 : 59–72. [Google Scholar]
  6. Holzenberger M, Hamard G, Zaoui R, et al. IGF-I receptor gene dosage generates a sexually dimorphic pattern of organ-specific growth deficits, affecting fat tissue in particular. Endocrinology 2001; 142 : 4469–78. [Google Scholar]
  7. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates life span and resistance to oxidative stress in mice. Nature 2003; 421 : 182–7. [Google Scholar]
  8. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402 : 309–13. [Google Scholar]
  9. Wolkow CA, Kimura KD, Lee MS, Ruvkun G. Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science 2000; 290 : 147–50. [Google Scholar]
  10. Alcedo J, Kenyon C. Regulation of C. elegans longevity by specific gustatory and olfactory neurons. Neuron 2004; 41 : 45–55. [Google Scholar]
  11. Murphy CT, McCarroll SA, Bargmann CI, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 2003; 424 : 277–84. [Google Scholar]
  12. Hwangbo DS, Gershman B, Tu MP, et al. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 2004; 429 : 562–6. [Google Scholar]
  13. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci USA 2001; 98 : 6736–41. [Google Scholar]
  14. Coschigano KT, Holland AN, Riders ME, et al. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 2003; 144 : 3799–810. [Google Scholar]
  15. Entingh-Pearsall A, Kahn CR. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 2004; 279 : 38016–24. [Google Scholar]
  16. Baba T, Shimizu T, Suzuki Y, et al. Estrogen, insulin, and dietary signals cooperatively regulate longevity signals to enhance resistance to oxidative stress in mice. J Biol Chem 2005; 280 : 16417–26. [Google Scholar]
  17. Blüher M, Kahn B, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003; 299 : 572–4. [Google Scholar]
  18. Roth GS, Lane MA, Ingram DK, et al. Biomarkers of caloric restriction may predict longevity in humans. Science 2002; 297 : 811. [Google Scholar]
  19. Paolisso G, Barbieri M, Rizzo MR, et al. Low insulin resistance and preserved beta-cell function contribute to human longevity but are not associated with TH-INS genes. Exp Gerontol 2001; 37 : 149–56. [Google Scholar]
  20. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390 : 45–51. [Google Scholar]
  21. Nabeshima Y. Challenge of overcoming aging-related disorders. J Dermatol Sci 2000; 24 (suppl 1) : S15–21. [Google Scholar]
  22. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309 : 1829–33. [Google Scholar]
  23. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone Klotho. J Biol Chem 2005; 280 : 38029–34. [Google Scholar]
  24. Holzenberger M, Martín-Crespo RM, Vicent D, Ruiz-Torres A. Decelerated growth and longevity in men. Arch Gerontol Geriat 1991; 13 : 89–101. [Google Scholar]
  25. Samaras TT, Storms LH. Impact of height and weight on life span. Bull WHO 1992; 70 : 259–67. [Google Scholar]
  26. Bonafe M, Barbieri M, Marchegiani F, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity : cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab 2003; 88 : 3299–304. [Google Scholar]
  27. van Heemst D, Beekman M, Mooijaart SP, et al. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 2005; 4 : 79–85. [Google Scholar]
  28. Chanson P. Complications cardiovasculaires de l’acromégalie. In : Chanson P, ed. Les conséquences de l’acromégalie. Cachan : Éditions Médicales Internationales, 2001: 27–41. [Google Scholar]
  29. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly : a retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab 1998; 83 : 2730–4. [Google Scholar]
  30. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89 : 667–74. [Google Scholar]
  31. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 2003; 58 : 86–91. [Google Scholar]
  32. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center : predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004; 89 : 2789–96. [Google Scholar]
  33. Drake WM, Howell SJ, Monson JP, Shalet SM. Optimizing GH therapy in adults and children. Endocrine Rev 2001; 22 : 425–50. [Google Scholar]
  34. Maison P, Griffin S, Nicoue-Beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults : a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004; 89 : 2192–9. [Google Scholar]
  35. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85 : a cohort study. Lancet 2002; 360 : 273–7. [Google Scholar]
  36. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk : a prospective study. Science 1998; 279 : 563–6. [Google Scholar]
  37. Raynaud-Simon A, Lafont S, Berr C, et al. Plasma insulin-like growth factor I levels in the elderly : relation to plasma dehydroepiandrosterone sulfate levels, nutritional status and mortality. Gerontology 2001; 47 : 198–206. [Google Scholar]
  38. Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today 2003; 69 : 257–71. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.